Targeted Therapies in CLL/SLL: Treatment Sequencing and Adverse Events Management
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and TG Therapeutics, Inc.
Click Here to Manage Email Alerts
Release date: January 31, 2022
Expiration date: January 31, 2023
Estimated time to complete: 2 hours
Jointly provided by
B-cell non-Hodgkin lymphoma management has advanced significantly in recent years, and patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been beneficiaries of these advances. However, studies have shown that as many as 40% of patients with CLL/SLL undergoing treatment with novel agents discontinue therapy—the majority of which do so because of adverse events (AEs)—and data suggest that the management of AEs is not consistent with recommendations. Moreover, despite advances in treatment, many patients will relapse, and subsequent treatment decisions are challenging. Real-world and prospective data regarding the impact of treatment sequence on patient outcomes are just emerging, and there is no guidance on sequencing therapies for patients who discontinue first-line therapy due to toxicity or progression.
Developed to help hematologist-oncologists, medical oncologists, and other health care providers (HCPs) keep pace with recommended AE management strategies and emerging data for treatment sequencing, this symposium will feature evidence-based presentations interspersed with real-world patient cases designed to provide learners with expert faculty insights and analysis of the clinical implications of new and emerging data for minimizing treatment-emergent AEs and managing treatment sequencing decisions in patients with CLL/SLL.
This activity has been designed for hematologist-oncologists, medical oncologists, and other HCPs involved in the care of patients with CLL/SLL.
Upon completion of this activity, participants should be better able to:
- Identify the safety profiles of the novel targeted agents used to treat CLL/SLL
- Outline treatment adjustments based on current and emerging data to effectively mitigate AEs while still achieving the deepest and most durable response
- Evaluate recent data on novel treatment sequencing strategies for managing relapsed/refractory CLL/SLL and their potential implications for clinical practice
Lindsey E. Roeker, MD—Program Chair
Assistant Attending L1
Memorial Sloan Kettering Cancer Center
New York, New York
Joanna M. Rhodes, MD, MSCE
Assistant Professor of Medicine
CLL Research and Treatment Program, Northwell Health Cancer Institute; Donald and Barbara Zucker School of Medicine
New Hyde Park, New York
Chaitra S. Ujjani, MD
University of Washington/Fred Hutchinson Cancer Research Center
Tarun Wasil, MBBS
Medical Oncologist and Hematologist
New York Cancer & Blood Specialists
Lake Success, New York
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences, the Lymphoma Research Foundation, and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Physicians: Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced practice nurses, nurses, and physician assistants may participate in this educational activity and earn a letter of attendance as American Academy of Nurse Practitioners (AANP), American Nurses Credentialing Center (ANCC), and American Academy of Physician Assistants (AAPA) accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Method of Participation
There are no fees to participate in this activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content.
To receive continuing education (CE) credit, participants must complete the posttest (achieving a passing grade of 70% or greater) and program evaluation. Certificates can be printed immediately.
To help ensure content objectivity, independence, and fair balance and to ensure that the content is aligned with the interest of the public, this content has been reviewed by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by Mansi R. Shah, MD, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Division of Blood Disorders, Leukemia/Lymphoma/Hematologic Malignancies, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
This activity was pilot-tested for time required for participation by Pallavi Kumar, MD, Jieqi Liu, MD, and Aakash Patel, MD.
According to the disclosure policy of Rutgers Biomedical and Health Sciences and to conform with Joint Accreditation requirements and FDA guidelines, individuals who are in a position to control the content of this educational activity are required to disclose to activity participants the existence of any relevant relationships with any ineligible company (ie, a company whose primary business is producing, marketing, selling, reselling, or distributing health care goods used by or on patients) within the past 24 months. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
The faculty have the following relevant financial relationships with ineligible companies:
Joanna M. Rhodes, MD, MSCE
Advisory Board: AbbVie, BeiGene, Genentech, Pharmacyclics, TG Therapeutics, Verastem Oncology
Consultant: AbbVie, BeiGene, Genentech, Pharmacyclics, TG Therapeutics
Medical Review: AstraZeneca
Presenter/Attendee: Curio Science
Lindsey E. Roeker, MD
Advisory Board: AbbVie, AstraZeneca, BeiGene, Janssen, Loxo Oncology, TG Therapeutics
Consultant: AbbVie, AstraZeneca, Nurix, Pharmacyclics, Pfizer, TG Therapeutics
Minority ownership interest: AbbVie, Abbott Laboratories
Research funding paid to institution: Pfizer
Speaker: Vaniam Group
Chaitra S. Ujjani, MD
Consultant: Atara, AstraZeneca, AbbVie, ACD Therapeutics, BeiGene, Epizyme, TG Therapeutics, Pharmacyclics
Tarun Wasil, MBBS
Stocks/Stock Options: Affimed, Aprea Therapeutics, Biocryst Pharmaceuticals, Bionano Genomics, Crispr Therapeutics, Fate Therapeutics, Gilead Sciences, Halozyme Therapeutics, Incyte, Infinity Pharmaceuticals, Iovance Biotherapeutics, Macrogenics, Mei Pharma, Mirati Therapeutics, Moderna, Oncternal Therapeutics, Personalis, Regeneron Pharmaceuticals, TG Therapeutics
Mansi R. Shah, MD, has no relevant financial relationships with ineligible companies to disclose.
Pallavi Kumar, MD, Jieqi Liu, MD, and Aakash Patel, MD have no relevant financial relationships with ineligible companies to disclose.
Rutgers Biomedical and Health Sciences
Patrick Dwyer, Director, Continuing Medical Education, has no relevant financial relationships with ineligible companies to disclose.
Lymphoma Research Foundation
Sarah Quinlan, Senior Director of Programs and Strategy, has the following relevant financial relationships with ineligible companies:
Advisory Board: Pfizer
Yvette M. Murley, PhD, Medical Director; Heather Rafa, Program Manager; Jonathan S. Simmons, ELS, Senior Managing Editor; Karen Smith, Creative Director, have no relevant financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed have been mitigated.
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rutgers Biomedical and Health Sciences, the Lymphoma Research Foundation, RedMedEd, or any manufacturer of pharmaceuticals or devices. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Rutgers Biomedical and Health Sciences; the Lymphoma Research Foundation; RedMedEd; AstraZeneca Pharmaceuticals; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and TG Therapeutics, Inc. do not recommend the use of any agent outside the labeled indications.
A computer, Apple iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android devices (OS 11 or higher) with an Internet connection using one of these browsers: Chrome, Firefox, Safari, Microsoft Edge
Copyright © 2022. Rutgers Biomedical and Health Sciences and RedMedEd. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers Biomedical and Health Sciences or RedMedEd.
For questions or concerns regarding this activity, please email Rutgers Biomedical and Health Sciences at firstname.lastname@example.org.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or email@example.com.